Industry News

Illumina, Inc. and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will...

Codiak BioSciences, a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines...

Mursla, a liquid biopsy company, has raised £410K from the UK Government’s Future Fund and existing investors. In addition, the organisation has secured a £40K COVID-19 grant from the Cambridgeshire Capital Grant Scheme. The funding will enable Mursla to finalise ...

Kimera Labs, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera’s first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes.  ...

Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor...

miR Scientific, LLC, a healthcare company whose purpose is to transform cancer management by providing early and highly accurate detection, characterization and monitoring of disease, today announced the publication of validation data...

Aethlon Medical a therapeutic medical device and technology company focused on unmet needs in oncology and viral diseases announced today that the National Institute for Dental and Craniofacial Research (NIDCR), a unit of the National Institutes for...

Mantra Bio today announced it has raised $25 million in a Series A financing to advance development of next generation, precision therapeutics based on...

Scientists have found that proteins, lipids, metabolites, and nucleic acids delivered by exosomes into cells can alter their biological response, which can promote or restrain the specific disease. They have been proved to be related with immune responses, viral pathogenicity, ...

BrainStorm Cell Therapeutics Inc, a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has successfully completed its first milestone in developing an innovative exosome-based platform-technology for the treatment severe COVID-19 infection. COVID-19 induced pneumonia ...